Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: Results from a phase III randomized trial

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 668-677

  Sieper, J ^a   Landewe R ^b,m   Rudwaleit, M ^c   Van Der Heijde, D ^d   Dougados, M ^e   Mease, P J ^f   Braun, J ^g   Deodhar, A ^h   Kivitz, A ⁱ   Walsh, J ^j   Hoepken, B ^k   Nurminen, T ^k   Maksymowych, W P ^l  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Endokrinologikum Berlin   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Institut Cochin   (France)

^f UNIVERSITY OF WASHINGTON   (United States)

^g RHEUMAZENTRUM RUHRGEBIET   (Germany)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ Altoona Center for Clinical Research   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k UCB PHARMA   (Belgium)

^l UNIVERSITY OF ALBERTA   (Canada)

^m Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; PLACEBO; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONDYLARTHRITIS; ADULT; AGED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CERTOLIZUMAB PEGOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SPONDYLARTHRITIS; TREATMENT OUTCOME;

EID: 84923588349     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38973     Document Type: Article

References (27)

1. Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
2. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
3. Mease PJ, Tubergen A, Deodhar A, Coteur G, Nurminen T, van der Heijde D,. Comparing health-related quality of life across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: analyses from certolizumab pegol clinical trial baseline data [abstract]. Ann Rheum Dis 2013; 72 Suppl 3: A766-7.
4. Poddubnyy D,. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis 2013; 5: 45-54.
5. European Medicines Agency (EMA). Annex 1: Summary of Product Characteristics (Humira) 2012. URL: http://www.ema.europa.eu/ema/.
6. European Medicines Agency (EMA). Annex 1: Summary of Product Characteristics (Cimzia) 2013. URL: http://www.ema.europa.eu/ema/.
7. European Medicines Agency (EMA). Annex 1: Summary of Product Characteristics (Enbrel) 2014. URL: http://www.ema.europa.eu/ema/.
8. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59: 1270-8.
9. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012; 71: 661-7.
10. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-52.
11. Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-9.
12. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych W, Mease P, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
13. Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid improvements in patient-reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis: 24-week results of RAPID-axSpA Study [abstract]. Ann Rheum Dis 2013; 72 Suppl 3: A287.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
15. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M,. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.
16. Ware JE Jr, Snow KK, Kosinski M, Gandek B,. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
17. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A,. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8.
18. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
19. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2: ii1-44.
20. Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al, for the Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1811-8.
21. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
22. Helliwell PS, Doward L, Whalley D, Tennant A, McKenna S, Reynolds S, et al. Psychometric and scaline properties of a new quality of life instrument specific to ankylosing spondylitis [abstract]. Arthritis Rheum 1999; 42 Suppl: S72.
23. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, et al. Spondyloarthritis Research Consortium of Canada Magnetic Resonance Imaging Index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005; 53: 703-9.
24. Mease PJ, van Tubergen A, Deodhar A, Coteur G, Nurminen T, van der Heijde D,. Comparing health-related quality of life across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: analyses from certolizumab pegol clinical trial baseline data [abstract]. Value Health 2013; 16: A570. URL: http://www.valueinhealthjournal.com/article/S1098-3015(13)03433-5/pdf.
25. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60: 717-27.
26. Sieper J, van der Heijde D, Dougados M, Van den Bosch F, Goupille P, Sarkar S, et al. Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis: week 68 results from ABILITY 1 [abstract]. Ann Rheum Dis 2012; 71 Suppl 3: 248.
27. Papp KA, Fonjallaz P, Casset-Semanaz F, Krueger JG, Wittkowski KM,. Analytical approaches to reporting long-term clinical trial data. Curr Med Res Opin 2008; 24: 2001-8.